18 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
13 May 24
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
8:18am
investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively
Continued strong recruitment for the pivotal … a 12-week, parallel design study and a 12-week randomized withdrawal study for stable responders.
oSince beginning recruitment in November 2023
8-K
EX-99.2
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
TETRAS ADL* scale
11 Alignment with FDA on dose and primary endpoint Phase 3 program design structured around the patient needs Robust recruitment
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
).
oEssential3 has over 3,000 referrals who have met the pre-qualifying eligibility criteria from the ongoing recruitment campaign started in November 2023
8-K
EX-99.1
xv87umllqmrux4xix5
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
0pzej43
16 Aug 21
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
8:04am
DEF 14A
lk5v3
29 Apr 21
Definitive proxy
4:04pm
10-K
1c3yni5f 1de4hks
17 Mar 21
Annual report
8:33am
10-Q
vtanzgghb 3rtmf7o
23 Nov 20
Quarterly report
4:16pm
424B4
msdy4g2 823tyse43
16 Oct 20
Prospectus supplement with pricing info
4:02pm
S-1/A
lbja9k8 emy27ylne
9 Oct 20
IPO registration (amended)
6:09am
S-1
pjvqusp
25 Sep 20
IPO registration
5:19pm
DRS/A
thgnoz q86m
28 Aug 20
Draft registration statement (amended)
12:00am
DRS
yhd vq5lwu2yl
22 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next